{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:06:01Z","timestamp":1792800361763,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T00:00:00Z","timestamp":1578009600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T00:00:00Z","timestamp":1578009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006313","name":"Barncancerfonden","doi-asserted-by":"publisher","award":["PR2014-0065"],"award-info":[{"award-number":["PR2014-0065"]}],"id":[{"id":"10.13039\/501100006313","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Neuroblastoma-CNS Network Foundation","award":["NCP2016-0023"],"award-info":[{"award-number":["NCP2016-0023"]}],"id":[{"id":"https:\/\/ror.org\/034a8v770","id-type":"ROR","asserted-by":"crossref"}]},{"name":"ALF-Lund University","award":["ALF 2015-2018"],"award-info":[{"award-number":["ALF 2015-2018"]}],"id":[{"id":"https:\/\/ror.org\/012a77v79","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100011077","name":"Sk\u00e5nes universitetssjukhus","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100011077","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009780","name":"Region Sk\u00e5ne","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100009780","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The European Union\u00b4s Horizon 2020 Research and Innovation program","award":["H2020-MSCA-Cofound-754299"],"award-info":[{"award-number":["H2020-MSCA-Cofound-754299"]}],"id":[{"id":"https:\/\/ror.org\/019w4f821","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glioblastomas (GBM) are therapy-resistant tumors with a profoundly immunosuppressive tumor microenvironment. Chemotherapy has shown limited efficacy against GBM. Systemic delivery of chemotherapeutic drugs is hampered by the difficulty of achieving intratumoral levels as systemic toxicity is a dose-limiting factor. Although some of its effects might be mediated by immune reactivity, systemic chemotherapy can also inhibit induced or spontaneous antitumor immune reactivity. Convection-enhanced delivery of temozolomide (CED-TMZ) can tentatively increase intratumoral drug concentration while reducing systemic side effects. The objective of this study was to evaluate the therapeutic effect of intratumorally delivered temozolomide in combination with immunotherapy and whether such therapy can generate a cellular antitumor immune response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Single bolus intratumoral injection and 3-day mini-osmotic pumps (Alzet\u00ae) were used to deliver intratumoral TMZ in C57BL6 mice bearing orthotopic gliomas. Immunotherapy consisted of subcutaneous injections of irradiated GL261 or KR158 glioma cells. Tumor size and intratumoral immune cell populations were analyzed by immunohistochemistry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Combined CED-TMZ and immunotherapy had a synergistic antitumor effect in the GL261 model, compared to CED-TMZ or immunotherapy as monotherapies. In the KR158 model, immunization cured a small proportion of the mice whereas addition of CED-TMZ did not have a synergistic effect. However, CED-TMZ as monotherapy prolonged the median survival. Moreover, TMZ bolus injection in the GL261 model induced neurotoxicity and lower cure rate than its equivalent dose delivered by CED. In addition, we found that T-cells were the predominant cells responsible for the TMZ antitumor effect in the GL261 model. Finally, CED-TMZ combined with immunotherapy significantly reduced tumor volume and increased the intratumoral influx of T-cells in both models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We show that immunotherapy synergized with CED-TMZ in the GL261 model and cured animals in the KR158 model. Single bolus administration of TMZ was effective with a narrower therapeutic window than CED-TMZ. Combined CED-TMZ and immunotherapy led to an increase in the intratumoral influx of T-cells. These results form part of the basis for the translation of the therapy to patients with GBM but the dosing and timing of delivery will have to be explored in depth both experimentally and clinically.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-019-6502-7","type":"journal-article","created":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T12:02:43Z","timestamp":1578052963000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6361-3272","authenticated-orcid":false,"given":"Julio","family":"Enr\u00edquez P\u00e9rez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Kopecky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Visse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4326-8149","authenticated-orcid":false,"given":"Anna","family":"Darabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Siesj\u00f6","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,3]]},"reference":[{"issue":"17","key":"6502_CR1","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1001\/jama.2013.280319","volume":"310","author":"A Omuro","year":"2013","unstructured":"Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013;310(17):1842\u201350.","journal-title":"JAMA"},{"issue":"3","key":"6502_CR2","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ccell.2017.02.009","volume":"31","author":"Daniela F. Quail","year":"2017","unstructured":"Quail DF, Joyce JA. The Microenvironmental Landscape of Brain Tumors. Cancer Cell. 2017;31(3):326\u201341","journal-title":"Cancer Cell"},{"issue":"21","key":"6502_CR3","doi-asserted-by":"publisher","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-17-2769","volume":"24","author":"RA Buerki","year":"2018","unstructured":"Buerki RA, Chheda ZS, Okada H. Immunotherapy of primary brain tumors: facts and hopes. Clin Cancer Res. 2018;24(21):5198\u2013205.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"6502_CR4","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40425-019-0536-x","volume":"7","author":"L Pinton","year":"2019","unstructured":"Pinton L, Masetto E, Vettore M, Solito S, Magri S, D'Andolfi M, et al. The immune suppressive microenvironment of human gliomas depends on the accumulation of bone marrow-derived macrophages in the center of the lesion. J Immunother Cancer. 2019;7(1):58.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"6502_CR5","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s11060-015-1720-6","volume":"122","author":"B Raychaudhuri","year":"2015","unstructured":"Raychaudhuri B, Rayman P, Huang P, Grabowski M, Hambardzumyan D, Finke JH, et al. Myeloid derived suppressor cell infiltration of murine and human gliomas is associated with reduction of tumor infiltrating lymphocytes. J Neuro-Oncol. 2015;122(2):293\u2013301.","journal-title":"J Neuro-Oncol"},{"issue":"10","key":"6502_CR6","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/s41416-018-0258-8","volume":"119","author":"NF Brown","year":"2018","unstructured":"Brown NF, Carter TJ, Ottaviani D, Mulholland P. Harnessing the immune system in glioblastoma. Br J Cancer. 2018;119(10):1171\u201381.","journal-title":"Br J Cancer"},{"issue":"11","key":"6502_CR7","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1080\/14712598.2018.1531846","volume":"18","author":"AM Swartz","year":"2018","unstructured":"Swartz AM, Shen SH, Salgado MA, Congdon KL, Sanchez-Perez L. Promising vaccines for treating glioblastoma. Expert Opin Biol Ther. 2018;18(11):1159\u201370.","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"6502_CR8","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.canlet.2006.12.012","volume":"252","author":"B Huang","year":"2007","unstructured":"Huang B, Lei Z, Zhao J, Gong W, Liu J, Chen Z, et al. CCL2\/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett. 2007;252(1):86\u201392.","journal-title":"Cancer Lett"},{"issue":"6","key":"6502_CR9","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1093\/neuonc\/nor042","volume":"13","author":"B Raychaudhuri","year":"2011","unstructured":"Raychaudhuri B, Rayman P, Ireland J, Ko J, Rini B, Borden EC, et al. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro-Oncology. 2011;13(6):591\u20139.","journal-title":"Neuro-Oncology"},{"issue":"9","key":"6502_CR10","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1093\/neuonc\/now034","volume":"18","author":"PR Gielen","year":"2016","unstructured":"Gielen PR, Schulte BM, Kers-Rebel ED, Verrijp K, Bossman SAJFH, ter Laan M, et al. Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8\/9 and arginase and suppress T cell function. Neuro-oncology. 2016;18(9):1253\u201364.","journal-title":"Neuro-oncology"},{"issue":"15","key":"6502_CR11","doi-asserted-by":"publisher","first-page":"4730","DOI":"10.1158\/1078-0432.CCR-06-0593","volume":"12","author":"EW Newcomb","year":"2006","unstructured":"Newcomb EW, Demaria S, Lukyanov Y, Shao Y, Schnee T, Kawashima N, et al. The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 Gliomas. Clin Cancer Res. 2006;12(15):4730\u20137.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"6502_CR12","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/ijc.23986","volume":"124","author":"KE Smith","year":"2009","unstructured":"Smith KE, Fritzell S, Badn W, Eberst\u00e5l S, Janelidze S, Visse E, et al. Cure of established GL261 mouse gliomas after combined immunotherapy with GM-CSF and IFN\u03b3 is mediated by both CD8 +and CD4 +T-cells. Int J Cancer. 2009;124(3):630\u20137.","journal-title":"Int J Cancer"},{"issue":"8","key":"6502_CR13","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s00262-011-1196-y","volume":"61","author":"S Eberst\u00e5l","year":"2012","unstructured":"Eberst\u00e5l S, Badn W, Fritzell S, Esbj\u00f6rnsson M, Darabi A, Visse E, et al. Inhibition of cyclooxygenase-2 enhances immunotherapy against experimental brain tumors. Cancer Immunol Immunother. 2012;61(8):1191\u20139.","journal-title":"Cancer Immunol Immunother"},{"issue":"1\u20132","key":"6502_CR14","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jneuroim.2014.06.019","volume":"274","author":"S Eberst\u00e5l","year":"2014","unstructured":"Eberst\u00e5l S, Fritzell S, Sand\u00e9n E, Visse E, Darabi A, Siesj\u00f6 P. Immunizations with unmodified tumor cells and simultaneous COX-2 inhibition eradicate malignant rat brain tumors and induce a long-lasting CD8+ T cell memory. J Neuroimmunol. 2014;274(1\u20132):161\u20137.","journal-title":"J Neuroimmunol"},{"issue":"1","key":"6502_CR15","doi-asserted-by":"publisher","first-page":"13902","DOI":"10.1038\/s41598-017-12584-0","volume":"7","author":"J Belmans","year":"2017","unstructured":"Belmans J, Van Woensel M, Creyns B, Dejaegher J, Bullens DM, Van Gool SW. Immunotherapy with subcutaneous immunogenic autologous tumor lysate increases murine glioblastoma survival. Sci Rep. 2017;7(1):13902.","journal-title":"Sci Rep"},{"issue":"1","key":"6502_CR16","doi-asserted-by":"publisher","first-page":"5632","DOI":"10.1038\/s41598-019-42001-7","volume":"9","author":"J Enr\u00edquez P\u00e9rez","year":"2019","unstructured":"Enr\u00edquez P\u00e9rez J, Fritzell S, Kopecky J, Visse E, Darabi A, Siesj\u00f6 P. The effect of locally delivered cisplatin is dependent on an intact immune function in an experimental glioma model. Sci Rep. 2019;9(1):5632.","journal-title":"Sci Rep"},{"issue":"3","key":"6502_CR17","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3171\/2014.5.JNS132392","volume":"121","author":"E Ishikawa","year":"2014","unstructured":"Ishikawa E, Muragaki Y, Yamamoto T, Maruyama T, Tsuboi K, Ikuta S, et al. Phase I\/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma: clinical article. J Neurosurg. 2014;121(3):543\u201353.","journal-title":"J Neurosurg"},{"issue":"2","key":"6502_CR18","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/CJI.0b013e3182811ae4","volume":"36","author":"RM Prins","year":"2013","unstructured":"Prins RM, Wang X, Soto H, Young E, Lisiero DN, Fong B, et al. Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients. J Immunother. 2013;36(2):152\u20137.","journal-title":"J Immunother"},{"issue":"5","key":"6502_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.molmed.2008.03.003","volume":"14","author":"R Yamanaka","year":"2008","unstructured":"Yamanaka R. Cell- and peptide-based immunotherapeutic approaches for glioma. Trends Mol Med. 2008;14(5):228\u201335.","journal-title":"Trends Mol Med"},{"issue":"5","key":"6502_CR20","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00280-006-0407-2","volume":"60","author":"S Brem","year":"2007","unstructured":"Brem S, Tyler B, Li K, Pradilla G, Legnani F, Caplan J, et al. Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model. Cancer Chemother Pharmacol. 2007;60(5):643\u201350.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"6502_CR21","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1007\/s00262-013-1449-z","volume":"62","author":"S Fritzell","year":"2013","unstructured":"Fritzell S, Sand\u00e9n E, Eberst\u00e5l S, Visse E, Darabi A, Siesj\u00f6 P. Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion. Cancer Immunol Immunother. 2013;62(9):1463\u201374.","journal-title":"Cancer Immunol Immunother"},{"issue":"370","key":"6502_CR22","doi-asserted-by":"publisher","first-page":"370ra180","DOI":"10.1126\/scitranslmed.aag2942","volume":"8","author":"D Mathios","year":"2016","unstructured":"Mathios D, Kim JE, Mangraviti A, Phallen J, Park C-K, Jackson CM, et al. Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM. Sci Transl Med. 2016;8(370):370ra180.","journal-title":"Sci Transl Med"},{"issue":"12","key":"6502_CR23","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1093\/neuonc\/noy072","volume":"20","author":"A Karachi","year":"2018","unstructured":"Karachi A, Dastmalchi F, Mitchell DA, Rahman M. Temozolomide for immunomodulation in the treatment of glioblastoma. Neuro-oncology. 2018;20(12):1566\u201372.","journal-title":"Neuro-oncology"},{"issue":"6","key":"6502_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1000412","volume":"8","author":"C Kilkenny","year":"2010","unstructured":"Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010;8(6):e1000412.","journal-title":"PLoS Biol"},{"issue":"3","key":"6502_CR25","doi-asserted-by":"publisher","DOI":"10.4161\/2162402X.2014.994374","volume":"4","author":"C Flores","year":"2015","unstructured":"Flores C, Pham C, Snyder D, Yang S, Sanchez-Perez L, Sayour E, et al. Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas. OncoImmunology. 2015;4(3):e994374.","journal-title":"OncoImmunology"},{"issue":"10","key":"6502_CR26","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987\u201396.","journal-title":"N Engl J Med"},{"issue":"10","key":"6502_CR27","first-page":"4148","volume":"6","author":"AB Heimberger","year":"2000","unstructured":"Heimberger AB, Archer GE, McLendon RE, Hulette C, Friedman AH, Friedman HS, et al. Temozolomide delivered by Intracerebral microinfusion is safe and efficacious against malignant Gliomas in rats. Clin Cancer Res. 2000;6(10):4148.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"6502_CR28","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s13311-017-0520-4","volume":"14","author":"AM Mehta","year":"2017","unstructured":"Mehta AM, Sonabend AM, Bruce JN. Convection-enhanced delivery. Neurotherapeutics. 2017;14(2):358\u201371.","journal-title":"Neurotherapeutics"},{"key":"6502_CR29","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jconrel.2017.12.020","volume":"271","author":"W Zhan","year":"2018","unstructured":"Zhan W, Wang CH. Convection enhanced delivery of chemotherapeutic drugs into brain tumour. J Control Release. 2018;271:74\u201387.","journal-title":"J Control Release"},{"issue":"12","key":"6502_CR30","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1007\/s00432-012-1290-3","volume":"138","author":"Jun Dong","year":"2012","unstructured":"Dong J, Zhou G, Tang D, Chen Y, Cui B, Dai X, et al. Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth. J Cancer Res Clin Oncol. 2012;138(12):2079\u201384.","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"key":"6502_CR31","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jconrel.2017.06.028","volume":"261","author":"MM Nordling-David","year":"2017","unstructured":"Nordling-David MM, Yaffe R, Guez D, Meirow H, Last D, Grad E, et al. Liposomal temozolomide drug delivery using convection enhanced delivery. J Control Release. 2017;261:138\u201346.","journal-title":"J Control Release"},{"issue":"5","key":"6502_CR32","doi-asserted-by":"publisher","first-page":"518","DOI":"10.3171\/2016.9.PEDS16152","volume":"19","author":"ACP Sewing","year":"2017","unstructured":"Sewing ACP, Lagerweij T, van Vuurden DG, Meel MH, Veringa SJE, Carcaboso AM, et al. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma. J Neurosurg Pediatr. 2017;19(5):518\u201330.","journal-title":"J Neurosurg Pediatr"},{"issue":"1","key":"6502_CR33","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3109\/10717544.2014.908248","volume":"23","author":"NU Barua","year":"2016","unstructured":"Barua NU, Hopkins K, Woolley M, O'Sullivan S, Harrison R, Edwards RJ, et al. A novel implantable catheter system with transcutaneous port for intermittent convection-enhanced delivery of carboplatin for recurrent glioblastoma. Drug Deliv. 2016;23(1):167\u201373.","journal-title":"Drug Deliv"},{"issue":"4","key":"6502_CR34","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1080\/1061186X.2017.1379526","volume":"26","author":"C-Y Lin","year":"2018","unstructured":"Lin C-Y, Li R-J, Huang C-Y, Wei K-C, Chen P-Y. Controlled release of liposome-encapsulated temozolomide for brain tumour treatment by convection-enhanced delivery. J Drug Target. 2018;26(4):325\u201332.","journal-title":"J Drug Target"},{"issue":"2","key":"6502_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3171\/2017.10.JNS171845","volume":"130","author":"MA Vogelbaum","year":"2018","unstructured":"Vogelbaum MA, Brewer C, Barnett GH, Mohammadi AM, Peereboom DM, Ahluwalia MS, et al. First-in-human evaluation of the Cleveland multiport catheter for convection-enhanced delivery of topotecan in recurrent high-grade glioma: results of pilot trial 1. J Neurosurg. 2018;130(2):1\u201310.","journal-title":"J Neurosurg"},{"issue":"2","key":"6502_CR36","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1093\/neuonc\/5.2.79","volume":"5","author":"M Westphal","year":"2003","unstructured":"Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology. 2003;5(2):79\u201388.","journal-title":"Neuro-oncology"},{"issue":"1","key":"6502_CR37","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.critrevonc.2010.09.001","volume":"80","author":"C Buonerba","year":"2011","unstructured":"Buonerba C, Di Lorenzo G, Marinelli A, Federico P, Palmieri G, Imbimbo M, et al. A comprehensive outlook on intracerebral therapy of malignant gliomas. Crit Rev Oncol Hematol. 2011;80(1):54\u201368.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"6502_CR38","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40263-016-0405-9","volume":"31","author":"MM Patel","year":"2017","unstructured":"Patel MM, Patel BM. Crossing the blood-brain barrier: recent advances in drug delivery to the brain. CNS Drugs. 2017;31(2):109\u201333.","journal-title":"CNS Drugs"},{"issue":"2","key":"6502_CR39","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3171\/2014.10.JNS14343","volume":"123","author":"TC Chen","year":"2015","unstructured":"Chen TC, Napolitano GR, Adell F, Sch\u00f6nthal AH, Shachar Y. Development of the metronomic biofeedback pump for leptomeningeal carcinomatosis: technical note. J Neurosurg. 2015;123(2):362\u201372.","journal-title":"J Neurosurg"},{"key":"6502_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coi.2015.10.009","volume":"39","author":"DH Munn","year":"2016","unstructured":"Munn DH, Bronte V. Immune suppressive mechanisms in the tumor microenvironment. Curr Opin Immunol. 2016;39:1\u20136.","journal-title":"Curr Opin Immunol"},{"issue":"14","key":"6502_CR41","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1158\/1078-0432.CCR-13-2057","volume":"20","author":"CM Jackson","year":"2014","unstructured":"Jackson CM, Lim M, Drake CG. Immunotherapy for brain Cancer: recent Progress and future promise. Clin Cancer Res. 2014;20(14):3651\u20139.","journal-title":"Clin Cancer Res"},{"issue":"7543","key":"6502_CR42","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/nature14320","volume":"519","author":"DA Mitchell","year":"2015","unstructured":"Mitchell DA, Batich KA, Gunn MD, Huang M-N, Sanchez-Perez L, Nair SK, et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature. 2015;519(7543):366.","journal-title":"Nature"},{"issue":"9","key":"6502_CR43","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1182\/blood-2001-12-0207","volume":"100","author":"M Ito","year":"2002","unstructured":"Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, et al. NOD\/SCID\/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood. 2002;100(9):3175\u201382.","journal-title":"Blood"},{"issue":"10","key":"6502_CR44","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1158\/0008-5472.CAN-14-0301","volume":"74","author":"D Alizadeh","year":"2014","unstructured":"Alizadeh D, Larmonier N. Chemotherapeutic targeting of Cancer-induced immunosuppressive cells. Cancer Res. 2014;74(10):2663\u20138.","journal-title":"Cancer Res"},{"issue":"7","key":"6502_CR45","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41571-018-0003-5","volume":"15","author":"M Lim","year":"2018","unstructured":"Lim M, Xia Y, Bettegowda C, Weller M. Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol. 2018;15(7):422\u201342.","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"6502_CR46","doi-asserted-by":"publisher","first-page":"3643","DOI":"10.1158\/1078-0432.CCR-18-2402","volume":"25","author":"JB Lamano","year":"2019","unstructured":"Lamano JB, Lamano JB, Li YD, DiDomenico JD, Choy W, Veliceasa D, et al. Glioblastoma-derived IL6 induces immunosuppressive peripheral myeloid cell PD-L1 and promotes tumor growth. Clin Cancer Res. 2019;25(12):3643\u201357.","journal-title":"Clin Cancer Res"},{"key":"6502_CR47","doi-asserted-by":"crossref","unstructured":"Alban TJ, Alvarado AG, Sorensen MD, Bayik D, Volovetz J, Serbinowski E, et al. Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis. JCI Insight. 2018;3(21):e122264.","DOI":"10.1172\/jci.insight.122264"},{"issue":"2","key":"6502_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.85841","volume":"1","author":"K Gabrusiewicz","year":"2016","unstructured":"Gabrusiewicz K, Rodriguez B, Wei J, Hashimoto Y, Healy LM, Maiti SN, et al. Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. JCI Insight. 2016;1(2):1\u201332.","journal-title":"JCI Insight"},{"issue":"1","key":"6502_CR49","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/ijc.22286","volume":"120","author":"KE Smith","year":"2007","unstructured":"Smith KE, Janelidze S, Visse E, Badn W, Salford L, Siesj\u00f6 P, et al. Synergism between GM-CSF and IFNgamma: enhanced immunotherapy in mice with glioma. Int J Cancer. 2007;120(1):75\u201380.","journal-title":"Int J Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6502-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-6502-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6502-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T19:12:32Z","timestamp":1609528352000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-6502-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,3]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["6502"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-6502-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,3]]},"assertion":[{"value":"13 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Animal procedures were approved by the ethical committee for animal research in Lund-Malm\u00f6, Dnr: M157\u201313 and M151\u201315 and were performed in accordance with the practices of the Swedish Board of Animal Research and European union animal rights and ethics directives.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7"}}